Shreyas Shirodkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shreyas Shirodkar has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Cumpston
Osborn Hematopoietic Malignancy and Cellular Therapy Program, West Virginia University, Morgantown, WV
1 shared publication Abraham S. Kanate
Osborn Hematopoietic Malignancy and Cellular Therapy Program, West Virginia University, Morgantown, WV
1 shared publicationAmir Kamran
Hematology/Oncology Department, Charleston Area Medical Center, Charleston, USA
1 shared publicationCarl Shultz
Osborn Hematopoietic Malignancy and Cellular Therapy Program, West Virginia University, Morgantown, WV
1 shared publicationChelby Wakefield
Osborn Hematopoietic Malignancy and Cellular Therapy Program, West Virginia University, Morgantown, WV
1 shared publicationJennifer Collins
Center for Health Services and Outcomes Research, Charleston Area Medical Center, Charleston, USA
1 shared publication
Latest Publications
- 19 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1415.e1-1415.e5
Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study
- 19 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1415.e1-1415.e5
Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study
- 25 December 2025
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (2) , 347-354
The impact of neutropenia severity in the setting of recent chemotherapy on mortality in sepsis
Background Sepsis and septic shock are major causes of non-relapse mortality in cancer patients, with chemotherapy-induced neutropenia increasing infection risk. The prognostic impact of neutropenia remains unclear across cancer subtypes. Patients and methods We conducted a retrospective cohort study using the TriNetX Research Network, comprising deidentified data from over 141 million patients across 105 U.S. health care organizations. Adults with select solid cancers who received chemotherapy and developed severe sepsis with septic shock from 2013 to 2024 were included. Patients were stratified by neutropenia severity (< 0.5 × 103/µL vs. 0.5–1.5 × 103/µL), and propensity score matching was applied to balance demographics, comorbidities, and treatment variables. Outcomes including short- and long-term mortality, organ failure, bacteremia, and immune-related adverse events were assessed using Kaplan–Meier survival analysis. Results Among 1083 eligible patients (184 severe, 899 mild–moderate neutropenia), severe neutropenia was associated with significantly worse survival at all timepoints, with median survival of 13 days versus 106 days and hazard ratios of 1.56–2.03 from 30 days to 1 year (all p < 0.001). Secondary outcomes showed no difference in immune-related adverse events, a nonsignificant trend toward increased organ failure, and higher rates of bacteremia in the severe neutropenia cohort. Conclusions Greater severity of chemotherapy-associated neutropenia is linked to worse short-term survival and increased complications in cancer patients with septic shock. Stratifying by neutrophil count bands revealed that severe neutropenia (< 0.5 × 103/µL) independently predicts poorer outcomes, emphasizing its value for risk stratification and guiding clinical management.
- 25 December 2025
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (2) , 347-354
The impact of neutropenia severity in the setting of recent chemotherapy on mortality in sepsis
Background Sepsis and septic shock are major causes of non-relapse mortality in cancer patients, with chemotherapy-induced neutropenia increasing infection risk. The prognostic impact of neutropenia remains unclear across cancer subtypes. Patients and methods We conducted a retrospective cohort study using the TriNetX Research Network, comprising deidentified data from over 141 million patients across 105 U.S. health care organizations. Adults with select solid cancers who received chemotherapy and developed severe sepsis with septic shock from 2013 to 2024 were included. Patients were stratified by neutropenia severity (< 0.5 × 103/µL vs. 0.5–1.5 × 103/µL), and propensity score matching was applied to balance demographics, comorbidities, and treatment variables. Outcomes including short- and long-term mortality, organ failure, bacteremia, and immune-related adverse events were assessed using Kaplan–Meier survival analysis. Results Among 1083 eligible patients (184 severe, 899 mild–moderate neutropenia), severe neutropenia was associated with significantly worse survival at all timepoints, with median survival of 13 days versus 106 days and hazard ratios of 1.56–2.03 from 30 days to 1 year (all p < 0.001). Secondary outcomes showed no difference in immune-related adverse events, a nonsignificant trend toward increased organ failure, and higher rates of bacteremia in the severe neutropenia cohort. Conclusions Greater severity of chemotherapy-associated neutropenia is linked to worse short-term survival and increased complications in cancer patients with septic shock. Stratifying by neutrophil count bands revealed that severe neutropenia (< 0.5 × 103/µL) independently predicts poorer outcomes, emphasizing its value for risk stratification and guiding clinical management.